Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04344795
Title Phase 1a/1b Study of TPST-1495 Alone and With Pembrolizumab in Subjects With Solid Tumors
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Tempest Therapeutics
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
University of Colorado Aurora Colorado 80045 United States Details
Sidney Kimmel Cancer Center, Johns Hopkins School of Medicine Baltimore Maryland 21287 United States Details
Baystate Gynecologic Oncology Springfield Massachusetts 01107 United States Details
University of Michigan Rogel Cancer Center Ann Arbor Michigan 48109 United States Details
START Midwest Grand Rapids Michigan 49546 United States Details
Carolina BioOncology Institute Huntersville North Carolina 28078 United States Details
SCRI-OK Stephenson Cancer Center Oklahoma City Oklahoma 73104 United States Details
University of Pennsylvania Perelman School of Medicine Philadelphia Pennsylvania 19104 United States Details
University of Pittsburgh Medical Center Pittsburgh Pennsylvania 15213 United States Details
Tennessee Oncology Nashville Tennessee 37203 United States Details
South Texas Accelerated Research Therapeutics (START) San Antonio Texas 78229 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field